Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 378, P. 390 - 401
Published: Dec. 20, 2024
Language: Английский
Nature Reviews Clinical Oncology, Journal Year: 2025, Volume and Issue: unknown
Published: March 6, 2025
Language: Английский
Citations
1
Theranostics, Journal Year: 2024, Volume and Issue: 15(3), P. 965 - 992
Published: Dec. 2, 2024
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, particularly due to the limited effectiveness current therapeutic options for advanced-stage disease. The efficacy traditional treatments is often compromised by intricate liver microenvironment and inherent heterogeneity. RNA-based therapeutics offer promising alternative, utilizing innovative approach targeting aberrant molecular pathways modulating tumor microenvironment. integration nanotechnology in this field, through development advanced nanocarrier delivery systems, especially lipid nanoparticles (LNPs), polymer (PNPs), bioinspired vectors, enhances precision RNA therapies. This review highlights significant progress nanotherapeutics HCC treatment, covering micro (miRNA), small interfering (siRNA), message (mRNA), activating (saRNA) mediated gene silencing, protein restoration, activation, cancer vaccines, concurrent therapy. It further comprehensively discusses prevailing challenges within landscape provides forward-looking perspective on potential transform treatment.
Language: Английский
Citations
5
APL Bioengineering, Journal Year: 2025, Volume and Issue: 9(1)
Published: March 1, 2025
Cancer-associated fibroblasts (CAFs) play a crucial role in the tumor microenvironment by promoting growth, immune evasion, and metastasis. Recently, drug delivery systems targeting CAFs have emerged as promising long-term effective approach to cancer treatment. Advances nanotechnology, particular, led development of nanomedicine designed specifically target CAFs, offering new possibilities for precise personalized therapies. This article reviews recent progress using nanocarriers that CAFs. Additionally, we explore potential combining multiple therapies, such chemotherapy immunotherapy, with enhance efficacy overcome resistance. Although many preclinical studies show promise, clinical application still faces considerable challenges, especially terms penetration large-scale production. Therefore, this review aims provide fresh perspective on CAF-targeted highlight future research directions applications.
Language: Английский
Citations
0
Journal of Rare Earths, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Citations
0
Polymer-Plastics Technology and Materials, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 27
Published: April 4, 2025
Language: Английский
Citations
0
Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 538 - 538
Published: April 21, 2025
Background: Cancer ranks as a leading cause of death worldwide. It is urgent to develop intelligent co-delivery systems for cancer chemotherapy achieve reduced side-effects and enhanced therapeutic efficacy. Methods: We chose oligo-hyaluronic acid (oHA, low molecular weight HA) the carrier, adriamycin (ADM) paclitaxel (PTX) co-delivered drugs. The oHA-ss-PTX macromolecular prodrug was synthesized by introducing glutathione-stimuli-responsive disulfide bonds through chemical reactions. Then, we constructed ADM-loading micelles (ADM/oHA-ss-PTX) in one step microfluidic preparation. delivery efficacy evaluated comprehensively vitro vivo. biocompatibility ADM/oHA-ss-PTX assessed hemolysis activity analysis, BSA adsorption testing, cell viability assay endothelial cells. Results: resulting possessed dynamic size (127 ± 1.4 nm, zeta potential −9.0 mV), high drug loading content approximately 21.2% 7.6% (ADM). Compared with free ADM+PTX, showed blood stability more efficiently inhibited proliferation. Moreover, due CD44-mediated endocytosis pathway, greater number were absorbed A549 cells than oHA-saturated In vivo experiments also that had excellent effects targeting ability. These results show promising platform sequential therapy CD44-positive cancer. Conclusions: conclusion, these convincingly demonstrate hold great promise novel co-delivering multiple Their properties not only validate this approach cancers but pave way future clinical translation further optimization treatment.
Language: Английский
Citations
0
Engineering materials, Journal Year: 2025, Volume and Issue: unknown, P. 297 - 329
Published: Jan. 1, 2025
Language: Английский
Citations
0
Assay and Drug Development Technologies, Journal Year: 2025, Volume and Issue: unknown
Published: May 7, 2025
Drug delivery systems are now being advanced by integrating sophisticated nanotechnologies to enhance therapeutic efficacy. Tremendous advancement has been achieved in the field of cancer therapy through utilization hyaluronic acid-based nanocarriers, which well-acknowledged for their capacity transport medication precisely targeted regions. Quantum dots exhibit unique optical properties that allow precise drug administration and monitoring capabilities. Carbon nanotubes provide a large surface area exceptional strength, allowing manipulation patterns. Dendrimers versatile structures can many drugs simultaneously, whereas mesoporous silica-functionalized nanoparticles exact release rate pharmaceuticals. Polymer-lipid hybrid synergistically integrate durability polymers with compatibility lipids, hence augmenting availability within body. Hexagonal boron nitride nanosheets becoming more recognized as favorable carriers due biocompatibility potential tailored administration. These achievements demonstrate changes happening pharmaceutical administration, where nanotechnology is used tackle issues such restricted bioavailability unanticipated adverse effects. This ultimately enhances effectiveness medicines improves patient outcomes. Future investigations will focus on improving these technologies broader applications.
Language: Английский
Citations
0
Journal of Controlled Release, Journal Year: 2024, Volume and Issue: 378, P. 390 - 401
Published: Dec. 20, 2024
Language: Английский
Citations
0